JP2002516900A5 - - Google Patents

Download PDF

Info

Publication number
JP2002516900A5
JP2002516900A5 JP2000552085A JP2000552085A JP2002516900A5 JP 2002516900 A5 JP2002516900 A5 JP 2002516900A5 JP 2000552085 A JP2000552085 A JP 2000552085A JP 2000552085 A JP2000552085 A JP 2000552085A JP 2002516900 A5 JP2002516900 A5 JP 2002516900A5
Authority
JP
Japan
Prior art keywords
compound
solvate
pharmaceutically acceptable
preparing
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000552085A
Other languages
English (en)
Japanese (ja)
Other versions
JP3554539B2 (ja
JP2002516900A (ja
Filing date
Publication date
Priority claimed from SE9801992A external-priority patent/SE9801992D0/xx
Application filed filed Critical
Publication of JP2002516900A publication Critical patent/JP2002516900A/ja
Application granted granted Critical
Publication of JP3554539B2 publication Critical patent/JP3554539B2/ja
Publication of JP2002516900A5 publication Critical patent/JP2002516900A5/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000552085A 1998-06-04 1999-05-31 新規な３−アリール−２−ヒドロキシプロピオン酸誘導体ｉ Expired - Fee Related JP3554539B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9801992A SE9801992D0 (sv) 1998-06-04 1998-06-04 New 3-aryl-2-hydroxypropionic acid derivative I
SE9801992-0 1998-06-04
PCT/SE1999/000941 WO1999062872A1 (en) 1998-06-04 1999-05-31 New 3-aryl-2-hydroxypropionic acid derivative (i)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2003273428A Division JP2004043480A (ja) 1998-06-04 2003-07-11 新規な３−アリール−２−ヒドロキシプロピオン酸誘導体ｉの中間体

Publications (3)

Publication Number Publication Date
JP2002516900A JP2002516900A (ja) 2002-06-11
JP3554539B2 JP3554539B2 (ja) 2004-08-18
JP2002516900A5 true JP2002516900A5 (enExample) 2005-04-28

Family

ID=20411587

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000552085A Expired - Fee Related JP3554539B2 (ja) 1998-06-04 1999-05-31 新規な３−アリール−２−ヒドロキシプロピオン酸誘導体ｉ
JP2003273428A Withdrawn JP2004043480A (ja) 1998-06-04 2003-07-11 新規な３−アリール−２−ヒドロキシプロピオン酸誘導体ｉの中間体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2003273428A Withdrawn JP2004043480A (ja) 1998-06-04 2003-07-11 新規な３−アリール−２−ヒドロキシプロピオン酸誘導体ｉの中間体

Country Status (39)

Country Link
US (5) US6258850B1 (enExample)
EP (1) EP1084103B1 (enExample)
JP (2) JP3554539B2 (enExample)
KR (1) KR100625152B1 (enExample)
CN (2) CN1311772A (enExample)
AR (2) AR020875A1 (enExample)
AT (1) ATE246674T1 (enExample)
AU (1) AU752261B2 (enExample)
BR (1) BR9910928A (enExample)
CA (1) CA2333938C (enExample)
CZ (1) CZ297424B6 (enExample)
DE (1) DE69910203T2 (enExample)
DK (1) DK1084103T3 (enExample)
DZ (1) DZ2800A1 (enExample)
EE (1) EE04772B1 (enExample)
EG (1) EG24140A (enExample)
ES (1) ES2205844T3 (enExample)
HR (1) HRP20000782B1 (enExample)
HU (1) HUP0103376A3 (enExample)
ID (1) ID28833A (enExample)
IL (1) IL139636A (enExample)
IS (1) IS2071B (enExample)
MA (1) MA26635A1 (enExample)
MY (1) MY117785A (enExample)
NO (1) NO323426B1 (enExample)
NZ (1) NZ508452A (enExample)
PL (1) PL195189B1 (enExample)
PT (1) PT1084103E (enExample)
RS (1) RS49688B (enExample)
RU (1) RU2214999C2 (enExample)
SA (1) SA99200304B1 (enExample)
SE (1) SE9801992D0 (enExample)
SK (1) SK284642B6 (enExample)
TN (1) TNSN99108A1 (enExample)
TR (1) TR200003581T2 (enExample)
TW (1) TW446696B (enExample)
UA (1) UA71912C2 (enExample)
WO (1) WO1999062872A1 (enExample)
ZA (1) ZA200006774B (enExample)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8702758D0 (en) * 1987-02-06 1987-03-11 Wellcome Found Treatment of disease
EP1629849B2 (en) 1997-01-07 2017-10-04 Amylin Pharmaceuticals, LLC Pharmaceutical compositions comprising exendins and agonists thereof
AU1198699A (en) * 1997-10-27 1999-04-23 Dr. Reddy's Research Foundation Novel heterocyclic compounds and their use in medicine, process for their reparation and pharmaceutical compositions containing them
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
SE9904415D0 (sv) * 1999-12-03 1999-12-03 Astra Ab New process
WO2001040171A1 (en) * 1999-12-03 2001-06-07 Astrazeneca Ab Crystalline form of (s)-2 ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid
TW574193B (en) * 1999-12-03 2004-02-01 Astrazeneca Ab Novel phenalkyloxy-phenyl derivatives, pharmaceutical composition containing the same and their uses
US7084177B2 (en) * 1999-12-03 2006-08-01 Astrazeneca Ab Comminuted form of(S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl] propanoic acid
SE9904421D0 (sv) 1999-12-03 1999-12-03 Astra Ab New compounds
DK1246638T4 (da) * 2000-01-10 2014-09-22 Amylin Pharmaceuticals Llc Anvendelse af extendiner og agonister deraf til behandlingen af hypertriglyceridæmi
US6559335B2 (en) 2000-09-22 2003-05-06 Dr. Reddy's Laboratories Limited Process for the preparation of 3-aryl-2-hydroxy propanoic acid
WO2002051441A1 (en) 2000-12-26 2002-07-04 Sankyo Company, Limited Medicinal compositions containing diuretic and insulin resistance-improving agent
SE0101386D0 (sv) 2001-04-20 2001-04-20 Astrazeneca Ab New compounds
SE0101982D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
SE0101981D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
SE0101980D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
SE0101978D0 (sv) 2001-06-01 2001-06-01 Astrazeneca Ab New compounds
JP2004528388A (ja) * 2001-06-01 2004-09-16 アストラゼネカ アクチボラグ ３−アリール−２−ヒドロキシプロピオン酸誘導体の製造法
PL368051A1 (en) 2001-06-07 2005-03-21 Eli Lilly And Company Modulators of peroxisome proliferator activated receptors
IL159320A0 (en) * 2001-06-12 2004-06-01 Wellstat Therapeutics Corp Compounds for the treatment of metabolic disorders
UA82835C2 (en) * 2001-12-03 2008-05-26 Reddys Lab Ltd Dr ?-aryl-?-oxysubstituted propionuc acid derivatives and pharmaceutical composition based thereon
GB0314079D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
SE0104333D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0229931D0 (en) * 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
WO2003059378A2 (en) 2001-12-29 2003-07-24 Novo Nordisk A/S Combined use of a glp-1 compound and another drug for treating dyslipidemia
SE0201005D0 (sv) * 2002-04-02 2002-04-02 Astrazeneca Ab New Process
US20050119314A1 (en) * 2002-04-05 2005-06-02 Sankyo Company, Limited Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent
US7351858B2 (en) * 2002-06-20 2008-04-01 Astrazeneca Ab Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
SE0201936D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
SE0201937D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
TWI282784B (en) * 2002-06-20 2007-06-21 Astrazeneca Ab Therapeutic agents
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
DE10308351A1 (de) 2003-02-27 2004-11-25 Aventis Pharma Deutschland Gmbh 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308355A1 (de) 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7148246B2 (en) 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
DE10308352A1 (de) 2003-02-27 2004-09-09 Aventis Pharma Deutschland Gmbh Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308353A1 (de) 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AP2005003462A0 (en) * 2003-06-06 2005-12-31 Cadila Healthcare Ltd Process for preparing 3-aryl-2-hydroxy propanoic acid derivatives without resolution.
GB0314075D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314131D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314078D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314130D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314260D0 (en) * 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents
CA2546601A1 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
JP2007512222A (ja) * 2003-11-27 2007-05-17 高砂香料工業株式会社 光学活性３−（４−ヒドロキシフェニル）プロピオン酸類の製造方法
EP1586573B1 (en) 2004-04-01 2007-02-07 Sanofi-Aventis Deutschland GmbH Oxadiazolones, processes for their preparation and their use as pharmaceuticals
US7799804B2 (en) 2004-04-03 2010-09-21 Astrazeneca Ab Therapeutic agents
FR2872159B1 (fr) * 2004-06-28 2007-10-05 Merck Sante Soc Par Actions Si Nouveaux derives acides carboxyliques phenyliques et leur utilisation dans le traitement du diabete
TW200608967A (en) 2004-07-29 2006-03-16 Sankyo Co Pharmaceutical compositions containing with diabetic agent
US8017633B2 (en) * 2005-03-08 2011-09-13 Nycomed Gmbh Roflumilast for the treatment of diabetes mellitus
DE102005026762A1 (de) 2005-06-09 2006-12-21 Sanofi-Aventis Deutschland Gmbh Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
WO2008010238A2 (en) * 2006-07-21 2008-01-24 Lupin Limited Antidiabetic azabicyclo [3. 1. 0] hexan compounds
KR100958831B1 (ko) * 2006-09-19 2010-05-24 주식회사유한양행 헤테로아릴피리미딘 유도체, 이들의 제조방법, 및 이들을포함하는 조성물
US20090082441A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched tesaglitazar
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
KR101890959B1 (ko) 2010-11-04 2018-08-22 알비레오 에이비 간질환 치료를 위한 ｉｂａｔ 억제제
CN103228270B (zh) 2010-11-08 2016-02-10 阿尔比里奥公司 含ibat抑制剂和胆汁酸结合剂的药物组合
WO2013041621A1 (de) 2011-09-20 2013-03-28 Basf Se Niedermolekulare modulatoren des kälte-menthol-rezeptors trpm8 und deren verwendung
BR112015024859A2 (pt) * 2013-03-27 2017-10-10 Pfizer Ireland Pharmaceuticals processo e intermediários para a preparação de pregabalina
MX2016000724A (es) * 2013-07-22 2016-04-13 Metabolic Solutions Dev Co Llc Compuestos de reserva de los receptores activados del proliferador de peroxisoma (ppar) para el tratamiento de enfermedades metabolicas.
CN120091812A (zh) 2022-11-08 2025-06-03 基恩菲特公司 用于治疗肝衰竭的PPARα/γ激动剂

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4114417A (en) * 1977-06-27 1978-09-19 Schmelzer Corporation Method and apparatus for making metal parts
US4479005A (en) * 1982-12-16 1984-10-23 The Dow Chemical Company Selective preparation of isomers and enantiomers of cyclopropane carboxylic acids
FR2653119B1 (fr) 1989-10-18 1994-08-05 Lipha Nouveaux aryloxy alcoyl benzenes, leurs procedes de preparation et les compositions pharmaceutiques en renfermant.
US5068345A (en) * 1989-10-30 1991-11-26 Eastman Kodak Company Oxazolidinone aldol adduct
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
GB9114948D0 (en) * 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP1000938A1 (en) * 1992-07-03 2000-05-17 Smithkline Beecham Plc Heterocyclic compounds as pharmaceuticals
US5232945A (en) 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
US5648541A (en) * 1995-09-28 1997-07-15 Nps Pharmaceuticals, Inc. Chiral reductions of imines leading to the syntheses of optically active amines
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
KR20000005224A (ko) * 1996-04-04 2000-01-25 가와무라 요시부미 페닐알킬카르복실산 유도체_
AU749505B2 (en) * 1997-10-27 2002-06-27 Dr. Reddy's Laboratories Limited Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
SE9801990D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl propionic acid derivatives and analogs
MA26634A1 (fr) * 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I

Similar Documents

Publication Publication Date Title
JP2002516900A5 (enExample)
RU2214999C2 (ru) Производное 3-арил-2-гидроксипропионовой кислоты, способ его получения(варианты), фармацевтический препарат, способ лечения и промежуточный продукт
RU2000130189A (ru) Новое производное i 3-арил-2-гидроксипропионовой кислоты
EP0668851B1 (en) A novel arylpropionic derivative, a process for the preparation and the use thereof as an analgesic agent
JP2002508375A5 (enExample)
CS208664B2 (en) Method of making the new r,s-n-/2-phenyl-2-hydroxyethyl/-1-alkyl-3-/4-substituted phenyl/propylamines
HK1006306B (en) A novel arylpropionic derivative, a process for the preparation and the use thereof as an analgesic agent
TW200920374A (en) Rosuvastatin calcium in solid state, pharmaceutical composition comprising the same, and use thereof
JP2002513793A5 (enExample)
HUP0200929A2 (en) Thiazolidinedione derivative and its use as antidiabetic and process for preparation thereof
JP6215399B2 (ja) ナルトレキソンの製造方法
JP2009161544A (ja) チアゾリジンジオン誘導体および抗糖尿病薬としてのその使用
JP2005513014A5 (enExample)
US6939856B2 (en) Method for preparing dexchlor tannate
HUP0100500A2 (hu) Az 5-[4-{2-[N-metil-N-(2-piridil)-amino]-etoxi}-benzil]-2,4-dioxo-tiazolidin-maleinsav-só hidrátja, eljárás az előállításukra és gyógyászati alkalmazása
KR20040020926A (ko) 중수소화된 엔-치환 및 α-치환 디페닐알콕시 아세트산아미노 알킬 에스테르 및 이 화합물을 포함한 의약품
CA1172170A (en) Antiviral alpha, alpha-dialkyl adamantylethylamines
JPH0725724B2 (ja) トラネキサム酸亜鉛化合物
KR100601244B1 (ko) 티아졸리딘디온 유도체 및 그의 당뇨병약으로서의 용도
RU2007143025A (ru) Полиморфизм додекагидроклопента[а]фенантренилового эфира тиофенкарбоновой кислоты
JP2003519683A5 (enExample)
JP2004532265A5 (enExample)
EP0030023A3 (en) A heterocyclic compound and its synthesis, pharmaceutical formulations thereof and the use of the compounds and the formulations in medicine
JPH033671B2 (enExample)
JP2003520835A5 (enExample)